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Abstract: Alcoholic pancreatitis continues to stir up controversy. One of the most debated 
points is whether from onset it is a chronic disease or whether it progresses to a chronic 
form  after  repeated  episodes  of  acute  pancreatitis.  Histological  studies  on  patients  with 
alcoholic pancreatitis have shown that the disease is chronic from onset and that alcoholic 
acute pancreatitis occurs in a pancreas already damaged by chronic lesions. Genetic factors 
may  also  play  a  role  in  the  pathogenesis  of alcoholic disease. The incidence of chronic 
alcoholic  pancreatitis  seems  to  have  decreased  in  the  last  twenty  years.  Finally,  recent 
therapeutic studies which have shown medical or surgical approaches capable of reducing 
the pain episodes in chronic pancreatitis patients will be described. 
Keywords:  alcoholic  pancreatitis;  pain;  gene  modification;  histology;  inflammation; 
patghogenesis; endoscopy; surgery 
 
1. Introduction 
 
Alcoholic pancreatitis as well as chronic pancreatitis of other etiologies is clinically characterized by 
frequent painful episodes in the early stages of the disease and then, over time, the pain attacks decrease 
in frequency and intensity in parallel with the progressive destruction of the gland. The pain tends to 
disappear during the natural course of the disease (the so-called "burn-out" phenomenon) or after a 
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period of time (ranging from a few years to a maximum of 10 years from the onset of the disease), and 
the destruction of the gland is clinically evident with the appearance of steatorrea and diabetes [1]. Pain 
significantly decreases the quality of life of chronic pancreatitis patients and sometimes leads to severe 
malnutrition [2]. The typical profile of a patient with chronic pancreatitis is that of a drinking male of 
about 40 years of age, with moderate pain intensity located in the epigastrium and radiating to the back, 
independent of food intake and lasting less than one day [3]. Of course, there is a small percentage of 
patients  who  have  persistent  abdominal  pain  and  this  group  of  subjects  represents  a  therapeutic 
challenge. On the other hand, in some patients, the disease may occur without pain (so-called painless 
pancreatitis) and the disease becomes clinically evident with the appearance of complications; this is the 
case  of  the  major  part  of  patients  having  autoimmune  pancreatitis  [4]  and  in  a  low  percentage  of 
patients with alcoholic pancreatitis. The most frequent complications of chronic pancreatitis are the 
following: obstructive jaundice, duodenal stenosis, left-sided portal hypertension, and pseudocyst and 
mass formation; pancreatic carcinoma may also occur as a complication of chronic pancreatitis [5]. In 
this paper we will review the epidemiological, pathological and clinical aspects of chronic pancreatitis as 
well as the recent advances in pancreatic pain treatment based on the papers appeared in the last decade. 
 
2. Epidemiology 
 
In 1998, Lankisch and Banks reported that the prevalence of chronic pancreatitis in many parts of the 
world appeared to be in the range of 3–10 per 100,000 people [6]. Most cases of chronic pancreatitis 
require hospitalization due to the presence of pain as well as to the appearance of other complications. 
In Italy, according to the data reported by the Department of the Welfare in 2005 [7], the rate of 
patients discharged for chronic pancreatitis is 32.9 per 100,000 hospitalized patients (Figure 1). The age 
of the major part of these patients ranges from 45 to 64 years (Figure 1) and the majority are males 
(Figure 2). The mean length of hospitalization is 9.8 days and this figure is higher as compared to that 
of all patients with diseases other than chronic pancreatitis (7.5 days). Finally, in Italy the trend of 
hospitalization for chronic pancreatitis seems to have decreased from 1999 to 2005 (Figure 3). There is 
no  doubt  that,  in  Western  countries,  alcohol  is  the  most  frequently  associated  factor  of  chronic 
pancreatitis, chronic alcoholic pancreatitis presents mainly in young adults of 30–40 years of age, and 
the prevalence is higher in the male gender. In these countries, in the period from 1940 to 2003, alcohol 
frequency increased as an etiological factor of chronic pancreatitis from 19 [8] to 50% [9] and even up 
to  80% [10-12]. The results of the latter study regarding the etiology of chronic pancreatitis were 
subsequently confirmed by others in Europe [13-19] as well as in Brazil [20], Australia [21] and South 
Africa [22]. 
On the other hand, four consecutive surveys carried out in Japan (from 1970 to 1977, from 1977 to 
1984, in 1994, and in 1999, respectively) [23] showed that alcohol as an etiological factor accounted for 
less than 60% and this figure is similar among the various periods studied.  
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Figure 1. Rate of patients discharged from the Italian hospitals in the year 2005 having the 
diagnosis of chronic pancreatitis and stratified according to age. 
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Figure 2. Rate of patients discharged from the Italian hospitals in the year 2005 having the 
diagnosis of chronic pancreatitis and stratified according to gender and age. 
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Figure 3. Trend in the rate of patients discharged from the Italian hospitals from 1999 to 
2005 having a diagnosis of chronic pancreatitis. 
 
 
3. The Importance of Alcohol as an Etiological Factor 
 
From a practical point of view, understanding the pathogenesis may lead to the identification of novel 
molecular targets and the development of new potential therapeutic agents. Thus, the role of alcohol is 
the  cornerstone  of  the  pathogenesis  of  chronic  pancreatitis.  Durbec  and  Sarles  [11]  have  clearly 
demonstrated that alcohol is a risk factor for chronic pancreatitis; in fact, they showed that the relative 
risk would be multiplied approximately by a factor of 1.4 per 20-gram increase in alcoholic intake. 
Furthermore, the risk appears to be more evident when passing from the class of non-drinkers to that of 
a 20-gram alcohol intake per day (relative risk of about 2); these data have been subsequently confirmed 
by others [24]. 
 
4. Changing Lifestyle Modifies the Alcoholic Etiology of Chronic Pancreatitis 
 
The impact of a changing lifestyle, especially in developing countries, may contribute to modifying 
the  etiology  of  chronic  pancreatitis.  For  example,  alcohol  consumption  in developing countries has 
increased  [25]  and  this  has  changed the etiology of chronic pancreatitis in those countries. On the 
contrary, in Europe, there was a progressive reduction of alcohol consumption from 1961 to 1991 [26] 
and the alcoholic form seems to have been reduced in frequency [3]. Furthermore, taking into account 
the lifestyle of chronic pancreatitis patients, it has been reported that the pancreatic functional changes 
caused by alcoholic pancreatitis progress even after the cessation of alcohol use, but the progression is 
slower and less severe when alcohol intake is stopped [27]. 
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5. Genetic Factors 
 
The  possibility  of  evaluating  the  mutations  of  the  cystic  fibrosis  transmembrane  conductance 
regulator-gene (CFTR-gene), as well as the discoveries of mutations of both the cationic trypsinogen 
gene (protease-serine-1 gene, PRSS-1) and the serine protease inhibitor, Kazal type 1 gene (SPINK-1), 
have led to better evaluating the hereditary forms in Western countries. 
In particular, Le Bodic et al. [28] found a link between hereditary pancreatitis and a locus on the 
long arm of chromosome 7 (7q33-qter), and Whitcomb et al. [29] better defined this finding, restricting 
the region of interest to 7q35. Whitcomb et al. [30] have also reported the identification of a mutation 
of the gene for cationic trypsinogen (PRSS1) in this region as the factor responsible for hereditary 
pancreatitis in the five families they studied. This mutation results in the modification of the cationic 
trypsinogen molecule, specifically the substitution of the arginine in position 122 with histidine. The 
authors  suggested  that  this  mutation  could  cause  interference  with  the  self-limiting  mechanisms  of 
cationic trypsinogen activation which, in the case of intraparenchymal activation of the enzyme, could 
determine an overactivation of the enzyme, with the consequent development of acute pancreatitis.  
Another  gene  examined  in  studying  of  chronic  pancreatitis  is  the  pancreatic  secretory  trypsin 
inhibitor (SPINK1). Witt et al. [31] found the modification of this gene in 22 of 96 young patients with 
chronic pancreatitis (28 hereditary pancreatitis, 68 idiopathic). The most significant mutation resulted in 
the substitution of asparagine in position 34 with serine. This mutation caused a loss in the efficacy of 
the  inhibition  of  trypsinogen  activation.  Mutations  in  the  pancreatic  secretory  trypsin  inhibitor  
(SPINK  1)  are  present  in  20%  of  subjects  with  idiopathic,  in  5%  of  those  with  alcoholic  chronic 
pancreatitis  and  in  50%  of  those  with  tropical pancreatitis; thus this gene is not able to determine 
chronic pancreatitis by itself, but seems capable of predisposing the disease in the presence of other 
precipitating factors [32].  
Mutations of CFTR may also play a role in the development of alcoholic pancreatitis. We studied 
mutations of CFTR in 98 patients of whom 34 had acute pancreatitis (20 of biliary origin, 14 alcoholic), 
46 had chronic pancreatitis (34 of alcoholic origin, one biliary, one autoimmune, 10 idiopathic) and 18 
had pancreatic cancer [33]. We found an elevated prevalence (17.4%) of CFTR mutations in the group 
of patients with chronic alcoholic pancreatitis and concluded that such mutations most likely have a 
predisposing role for the disease.  
Finally,  Verlaan  et  al.  [34]  studied  the  potential  role  of  the  polymorphisms  of  the  ADH3  and 
CYP2E1  genes  codifying  the  alcohol-metabolizing  enzymes  in  142  adult  patients  with  chronic 
pancreatitis (21 hereditary pancreatitis, 82 alcoholic origin, and 39 idiopathic) and found no evidence of 
association between these genes and pancreatitis.  
In conclusion, the PRSS1 mutations appear capable of inducing chronic pancreatitis whereas CFTR 
and SPINK-1 seem to be ―gene modifiers‖ capable of inducing the disease in the presence of a risk 
factor such as alcohol. 
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6. Modification of the Etiology  
 
The  changing  lifestyle  and  the  discovery  of  genetic  factors  associated  with  pancreatitis  may 
contribute  to  changing  the  frequencies  of  the  various  etiologies  of  chronic pancreatitis. This is the 
reason why, from 2004 to the present, the etiological features of chronic pancreatitis have been reported 
to be different than in the past. Four studies are examples of this. In Korea [35], the main etiological 
factor remains alcohol (64.3%), followed by an unknown etiology (20.8%), obstruction (8.6%) and 
autoimmune  pancreatitis  (2.0%).  In  a  recent  survey  on  chronic  pancreatitis  in  the  Asian-Pacific  
region [36], there was a great variability in the frequency of alcoholic pancreatitis, accounting for about 
19% of chronic pancreatitis cases in China up to 95% in Australia whereas tropical pancreatitis was 
46.4% in China and was, obviously, not present in Australia. In a recent survey of chronic pancreatitis 
in Italy [3], chronic pancreatitis associated with alcohol abuse accounted for less than 50% of cases and 
this figure is lower than that reported by Gullo et al. in 1977 [10]. However, some regional differences 
regarding the frequency of alcoholic chronic pancreatitis exist in Italy. In fact, in Bologna (located in 
Northern Italy), alcohol as an etiological factor remains high (80.4%) [37] whereas, in Sicily (located in 
the Southern Italy), the percentage of alcoholic chronic pancreatitis is about 60% [38]. In a survey of 
chronic pancreatitis in Italy 3], alcohol as an etiological factor of chronic pancreatitis is followed by 
obstruction (27%), pancreatitis of unknown origin (17%), autoimmunity (4%) and hereditary/genetic 
factors  (4%).  The  most  surprising  results  come  from  India.  In  a  prospective  nationwide  study  in  
India [39], the authors found that the majority of patients had pancreatitis of unknown origin (60% of 
the cases); alcoholic chronic pancreatitis accounted for a third of the cases whereas tropical pancreatitis 
was present in only 3.8% of the cases. It seems that alcohol tends to be increasing in frequency in India 
as is chronic pancreatitis of unknown etiology; the increase in the idiopathic form of the disease (60% of 
all forms of chronic pancreatitis are idiopathic) has not been explained well by the authors and may be 
due to an incomplete evaluation of the possible risk factors. In this regard, it is worth noting that the 
frequency of chronic pancreatitis of unknown origin is 17% in the Italian survey [3] ranging from about 
12% in Bologna to 38% in Sicily [38,39]. Thus, we need to spend more time with our patients when 
evaluating the possible factors determining their disease. 
 
7. Pathogenesis of Alcoholic Pancreatitis 
 
The mechanism which determines the main manifestation of chronic pancreatitis, i.e., fibrosis of the 
pancreatic gland, has been well summarized by Taludkar et al. [40]. In brief, the oxidation of ethanol to 
acetaldehyde determines the activation of the pancreatic stellate cells in the quiescent state without any 
pre-activation; this process generates a state of oxidant stress within the pancreatic stellate cells which 
subsequently activates the downstream pathways of the fibrogenesis. This finding implies that, in the 
human pancreas, pancreatic stellate cells may be stimulated early during chronic alcohol intake even in 
the  absence  of  necro-inflammation.  The  importance  of  the  oxidative  stress  in  chronic  pancreatitis 
patients has also been reported using breath analysis [41]. In this study, H2S, NO and a substance 
having a molecular mass of 66 u (M66) were those which had significantly higher breath concentrations 
in  chronic  pancreatitis  patients  than  in  healthy  subjects  after  adjustment  for  the  ambient  air;  no Int. J. Environ. Res. Public Health 2009, 6                 
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significant differences in H2S, M66, and NO were found between patients with and without alcoholic 
pancreatitis.  
Regarding the pancreatic stellate cells, in 1982, Watari et al. [42] reported the presence of vitamin 
A-containing cells in the vitamin A-fed rat pancreas. These were later described and characterized as 
stellate cells in the rat and the human pancreas [43,44]. Pancreatic stellate cells are morphologically 
similar to hepatic stellate cells. They have long cytoplasmic processes and are situated close to the 
pancreatic acini. In the quiescent state, these cells contain lipid droplets, store vitamin A and express 
markers such as desmin, glial fibrillary acidic protein, neural cell adhesion molecule and neurotrophin 
nerve growth factor just as hepatic stellate cells do. Pancreatic stellate cells contain enzyme alcohol 
dehydrogenase [45] and, when activated, they assume a myofibroblast-like phenotype [46]. Activated 
pancreatic stellate cells are characterized by the disappearance of fat globules and the expression of 
alpha-smooth muscle actin. These cells have proliferative and migratory [47-49] functions, and they also 
synthesize and secrete extracellular fibrous tissue matrix proteins, matrix metalloproteinases and their 
inhibitors [50]; it has also been demonstrated that pancreatic stellate cells have phagocytic activity [51]. 
Thus, the ability of pancreatic stellate cells to synthesize as well as to degrade extracellular matrix 
proteins suggests their role in maintaining a normal pancreatic architecture which can shift towards 
fibrogenesis if the balance is altered. Ethanol, acetaldehyde and oxidant stress are capable of activating 
pancreatic stellate cells via three mitogen-activated protein kinase pathways [52], namely extracellular 
signal kinase, p38 kinase and c-jun amino terminal kinase [53-55], and ethanol and acetaldehyde are also 
capable  of  activating  phosphatidylinositol  3-kinase  and  protein  kinase  C  [56].  On  the  other  hand, 
extracellular signal kinase activation occurs via a signal transduction pathway which involves G-protein 
Ras  and  serine  threonine  protein  kinase  Raf-1  [57,58].  The  Ras  superfamily  G  proteins  undergo  
post-translational  modification  involving  isoprenylation,  a  process  which  requires  intermediate 
substrates of cholesterol biosynthesis [59,60] which is regulated by HMG CoA reductase [61]. The 
paracrine pro-fibrogenic effect of TGF-beta on pancreatic stellate cells is mediated via Smad while the 
autocrine effect is mediated through the extracellular signal kinase pathway [62]; furthermore, the role 
of  the  peroxisome  proliferator-activated  receptor-gamma  seems  to  be  involved  in  the  activation  of 
pancreatic stellate cells [63,64]. 
The  major  parts  of  the  studies  published  on  pancreatic  stellate  cells  have  been  carried  out  on 
experimental animals; thus, the study of Suda et al. seems to be of particular interest because it was 
carried out on humans [65]. These authors investigated the distribution of activated pancreatic stellate 
cells  or  myofibroblasts  using  immunohistochemistry  and  a  computer-counting  device  in  relation  to 
fibrogenesis in 24 patients with clinically diagnosed chronic alcoholic pancreatitis. In all cases, fibrosis 
was  patchily  distributed  in  the  perilobular  or  interlobular  areas  accompanied  by  a  cirrhosis-like 
appearance; it had extended into the intralobular area in advanced cases. Seven patients had a massive 
or confluent loss of exocrine tissue, resulting in extensive interlobular fibrosis; the more extensive the 
interlobular  fibrosis,  the  smaller  the  lobules.  Immunoreactivity  to  alpha-smooth  muscle  actin,  a 
myofibroblast marker, was found mostly in the same areas of the fibrosis, mainly the interlobular and 
less  often  the  periacinar,  areas;  the  average  percentage  area  of  perilobular  myofibroblasts  was 
significantly higher than that of periacinar myofibroblasts in 20 randomly selected lobules; the fibrosis 
also  immunostained  positive  for  collagen  types  I  and  III.  In  conclusion,  this  study,  carried  out  on Int. J. Environ. Res. Public Health 2009, 6                 
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humans, further supports the hypothesis that the fibrotic alterations in chronic alcoholic pancreatitis are 
not due to recurrent episodes of necrotizing pancreatitis but the disease is due to a chronic stimulation 
of alcohol on pancreatic stellate cells which play an important role in pancreatic fibrogenesis. 
 
8. Histology of Alcoholic Pancreatitis 
 
According  to  the  previously  described  pathogenesis,  alcohol  seems  to  induce  pancreatic  fibrosis 
(Figure 4) as it has frequently been found in autoptic series of alcoholics without a clinical history of 
chronic  pancreatitis  [66-68].  Two  histological  studies  [69,70]  were  conducted  on  the  pancreata  of 
patients  at  the  time  of  their  first  attack  of  acute  alcoholic  pancreatitis, and both studies found the 
presence of chronic lesions in the acutely inflamed pancreas. Moreover, in a clinical study [71] of 114 
patients hospitalized for acute alcoholic pancreatitis as the first manifestation of pancreatic disease, a 
diagnosis of chronic pancreatitis was made in 105 (92%) of the 114 patients during the follow-up. 
These authors concluded that acute alcoholic pancreatitis without underlying chronic pancreatitis does 
not exist or is extremely rare.  
 
Figure 4. Typical pathological appearance of human chronic pancreatitis: Fibrosis, loss of 
acinar tissue, enlarged ducts and stones within some of them. 
 
 
Based on the data of the literature and on our experience, we believe that the great majority (>90%) 
of  alcoholic  patients  who  present  clinically  with  acute  pancreatitis  also  have  chronic  lesions.  The 
possibility that an alcoholic with acute pancreatitis has no chronic pancreatic lesions certainly cannot be 
excluded but, if this condition exists, it is rare [72]. 
A working hypothesis called ‗the necrosis-fibrosis sequence‘ has been also suggested for explaining 
the  pathogenesis  of  chronic  pancreatitis.  This  hypothesis  is  based  on  pancreatic  tissue  examination 
during alcoholic acute and chronic pancreatitis [73-75]. Early after the onset on pancreatitis symptoms 
there  is  evidence  of  postnecrotic  changes  such  as  pseudocystes;  and  morphology  from  surgical Int. J. Environ. Res. Public Health 2009, 6                 
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specimens  showing  predominant  pancreatic  lesions  of  focal  necrosis  and  mild  fibrosis.  In  contrast, 
specimens several years after the onset of symptoms obtained at autopsy show severe perilobular and 
intralobular fibrosis and calcification with no necrosis [76]. 
 
9. Alcohol and Pancreatic Inflammation  
 
Singh  et  al.  [77]  in  an  effort  to  develop  a  model of chronic alcoholic pancreatitis in rats fed a 
nutritionally adequate diet, three groups of animals each were fed ad libitum, Lieber-DeCarli diet with 
40% of carbohydrate calories replaced by ethanol ad libitum and isocaloric amounts of Lieber-DeCarli 
diet respectively for a period of 18 months. In these animals basal and secretin-stimulated pancreatic 
juice was obtained as well as pancreatic tissue for evaluating the presence of histological, biochemical 
analyses and cellular analyses. All of the ethanol-fed animals developed morphological changes akin to 
human chronic pancreatitis. In the pancreatic tissue of animals fed ethanol, total protein, trypsinogen 
and free trypsin were increased and amylase was decreased. While acid phosphatase was increased in all 
of  the  particulate  fractions,  cathepsin  B  was  increased  in  the  zymogen  granule  and  mitochondrial-
lysosomal  fractions.  Basal  and  post-secretin  pancreatic  juice  did  not  show  a  significant  increase  in 
digestive or lysosomal enzymes. Thus, the authors concluded that focal degenerative changes may be 
due  to  trypsin  generated  by  intracellular  activation  of  digestive  enzymes  by  lysosomal  enzyme  
cathepsin B.  
Gukovsky et al. [78] have recently found that rats which had been fed ethanol for 8 weeks and which 
had  received  cyclosporin  A  for  the  last  two  weeks  and  in  which  acute  pancreatitis  had  been  
cerulein-induced had a massive loss of acinar cells, persistent inflammatory infiltration and fibrosis as 
compared to the control animals receiving cyclosporin A plus cerulein. Furthermore, macrophages in 
the  treated  rats  were  prominent  in  the  inflammatory  infiltrate  and  showed  a  marked  increase  in 
pancreatic NF-kappaB activation, cytokine/chemokine mRNA expression, collagen and fibronectin, in 
the expression and activities of matrix metalloproteinases 2 and 9 and in the activation of pancreatic 
stellate  cells.  Therefore,  this  study  shows  the  possible  mechanism  by  which  alcohol  sensitizes  the 
pancreas to chronic injury.  
 
10. Alcohol and Pancreatic Pain  
 
The close relationship between inflammation and pain has been investigated by Michalski et al. [79]. 
They found that the responsiveness of peripheral blood mononuclear cells to the neuropeptide pituitary 
adenylate  cyclase-activating  polypeptide  is  altered  in  chronic  pancreatitis  patients.  In  fact,  the 
nociceptive  status  of  chronic  pancreatitis  patients  correlated  with  pancreatic  pituitary  adenylate  
cyclase-activating  polypeptide  levels  and  with  IL-10  bias  of  pituitary  adenylate  cyclase-activating 
polypeptide-exposed  peripheral  blood  mononuclear  cells  of  chronic  pancreatitis  patients.  Thus,  the 
ability  of  peripheral  blood  mononuclear  cells  to  produce  and  to  respond  to  pituitary  adenylate  
cyclase-activating polypeptide might influence the neuroimmune interactions which regulate pain and 
inflammation in chronic pancreatitis. 
The chronic inflammatory process produces a massive release of local lytic enzymes which leads to Int. J. Environ. Res. Public Health 2009, 6                 
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the  release  of  several  pro-inflammatory  cytokines  and  pro-fibrotic  agents,  such  as  TGF-beta1  and 
growth factor B derived from platelets and capable of inducing fibrosis. As a result of this process, there 
is also a mechanism of neurogenic inflammation mediated by transient receptor potential vanilloid-1 
(TRPV-1) [80,81]. Other receptors involved in this process are the T-type calcium channels (located on 
sensory intrapancreatic fibers) activated by hydrogen sulfide. The activation of peripheral nerve fibers 
determines the synthesis of substance P; the synthesis of substance P is also increased by protein 43 
which is overexpressed in chronic alcoholic pancreatitis. Substance P carries out many activities [82]: it 
stimulates  inflammatory  cells  to  produce  cytokines  through  the  neurokinin  1  receptor,  it  increases  
poly-morphonuclear cells, macrophages and fibroblasts locally and induces nerve regeneration, and it 
also  causes  a  vasoconstriction  of  arterioles  determining  ischemia  of  the  nervous  fibers  themselves. 
Moreover, pain in chronic pancreatitis is the result of the effect of somatic and visceral fibers which 
result in changes in neurons [83]. This phenomenon leads to a hyperalgesia mediated by the central 
nervous system even in the absence of a peripheral nociceptive stimulus. This mechanism is associated 
with a functional rearrangement of the cerebral cortex which leads to a "pain memory" over time and is 
independent of the peripheral input [36]. 
 
11. Other Causes of Pain in Chronic Pancreatitis 
 
Regarding the pancreatic causes of pain, recent studies [84,85] have shown a neuropathic origin of 
this  symptom,  i.e. normal pain signals in the presence of injury or disease of the peripheral and/or 
central nervous system. This is supported by Drewes et al. [86] who evaluated electroencephalography 
in chronic pancreatitis patients having pain. In these subjects, an increase in theta wave activity was 
found and this seemed to be a marker of neuropathic pain. Furthermore, it is also known that, in the 
pancreatic tissue of patients with chronic pancreatitis, there is an increase in the number and diameter of 
nerve  fibers  [86].  We  also  note  the  extrapancreatic  causes  of  pain  are  mainly  related  to  duodenal 
stenosis associated or not with stenosis of the main biliary duct [87]. 
 
12. Role of Alcoholic Chronic Pancreatitis in Pancreatic Cancer 
 
Several studies have linked chronic pancreatitis with an increased risk of pancreatic cancer [88]. The 
evidence comes from different types of studies, with case-control studies being the most frequent. Most 
of  these  studies  have  shown  that  when  compared  to  control  subjects  without  chronic  pancreatitis, 
patients with chronic pancreatitis have an increased risk of pancreatic cancer. However, these studies 
are subject to recall bias because patients with pancreatic cancer may be more likely to report a past 
history of pancreatitis than control subjects. Furthermore, because chronic pancreatitis is a rare disease, 
a large number of patients are necessary to be sure that a negative study is truly negative rather than 
being ―non-significant‖ as a result of the small sample size. Thus, cohort studies provide more reliable 
evidence of the link between chronic pancreatitis and pancreatic cancer. Several such studies have been 
carried out and all show an elevated risk of pancreatic cancer, even after excluding patients in whom 
there has been a short interval between the onset of pancreatitis and cancer [89].  
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13. A New Perspective for the Treatment of Intractable Pain in Chronic Alcoholic Pancreatitis 
Patients 
 
Regarding the therapeutic modalities in curing chronic pancreatitis patients, all studies enroll all types 
of  pancreatitis  and  there  are  no  specific  studies  only  for  the  alcoholic  form.  The  persistence  of 
pancreatic pain leads to surgery in 11% of patients and to endoscopic treatment in approximately 29% 
of the cases [3]. After surgical treatment, the disappearance of pain, or at least its substantial reduction, 
is observed in 67-94% in the short term whereas good results are achieved in 50-88% of the subjects 
over a long-term period [36]. Thus, we need adequate medical treatment, especially for those patients 
who do not benefit from surgical or endoscopic approaches. The traditional medical approach is based 
on  the  administration  of  long-acting  octreotide  [90],  tricyclic  antidepressants,  narcotics  or  a  celiac 
plexus  nerve  block  using  computed  tomography  or  echoendoscopy,  and  the  results  are  sometimes 
disappointing. For this reason, studies exploring additional techniques for alleviating pain in chronic 
pancreatitis patients are needed.  
 
13.1. Control of the Central Nervous System 
 
Kongkam et al. have evaluated the efficacy of the intrathecal narcotics pump [91]. They studied 13 
patients who had experienced intractable upper abdominal pain from chronic pancreatitis. Each patient 
had had other unsuccessful treatment modalities, including partial pancreatic resections in six patients. 
They were offered an intrathecal narcotics pump after a successful intraspinal opioid trial. The etiology 
of chronic pancreatitis was unknown in three subjects, due to cystic fibrosis in two and due to alcohol 
abuse  in  two;  pancreas  divisum  was  present  in  the  remaining  six  patients.  The  median duration of 
severe, intractable pain prior to the intrathecal narcotics pump was six years and the median follow-up 
time after the intrathecal narcotics pump was 29 months. The intrathecal narcotics pump was in situ for 
a mean duration of 29 months. Seven patients had a pump exchange or removal for various reasons, 
such as improvement of pain, meningitis, meningitis with subsequent replacement or pump failure. The 
mean pain score prior to implantation was significantly higher than that calculated one year after entry 
into the study. The median oral narcotic dose before and one year after the intrathecal narcotics pump 
were  morphine  sulfate  equivalents  of  337.5  mg/day  and  40  mg/day,  respectively  (P  <  0.01).  Two 
patients  were  considered  failures  as  they  still  required  a  high  dosage  of  both  oral  and  intrathecal 
medications  to  control  their  pain,  despite  significant  pain-score  improvement; one patient who was 
excluded due to meningitis was also considered a failure. Therefore, the overall success rate of the 
intrathecal narcotics pump based on an intention-to-treat analysis was 76.9%. The major complications 
of the intrathecal narcotics pump observed in 3 patients (23.1%) were central nervous system infection 
requiring  pump  removal,  cerebrospinal fluid leak requiring laminectomy and perispinal abscess with 
bacterial  meningitis  requiring  pump  removal.  This  study  shows  a  good  efficacy  of  the  intrathecal 
narcotics  pump  in  chronic  pancreatitis  patients  with  persistent  pain;  however,  as  previously  
reported [92], the risk of this therapeutic modality is high. Furthermore, we need longer follow-ups and 
especially therapeutic trials comparing pancreatectomy, the intrathecal narcotics pump and implanted 
nerve stimulators. Int. J. Environ. Res. Public Health 2009, 6                 
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13.2. Antoxidants 
 
Antioxidant  treatment  may  become  a  useful  tool  in  preventing  and  curing  pain  in  patients  with 
chronic pancreatitis. Data on this topic are under debate [93] because the majority of studies published 
are not randomized or are based on a low number of patients. Recently a placebo-controlled double 
blind trial has reported good results on pain relief using antioxidant supplementation on a large number 
of chronic pancreatitis patients [94]. In this study, consecutive patients with chronic pancreatitis were 
randomized to groups which were given placebo or antioxidants for six months. The primary outcome 
measure was pain relief; secondary outcome measures were analgesic requirements, hospitalization, and 
markers of oxidative stress and antioxidant status. One hundred and twenty-seven patients (86 male, 35 
alcoholic, and 92 with idiopathic chronic pancreatitis) were studied; fifty-six patients were assigned to 
the placebo group and 71 to the antioxidant group. After six months, the reduction in the number of 
painful days per month was significantly higher in the antioxidant group as compared to the placebo 
group. The reduction in the number of analgesic tablets per month was also higher in the antioxidant 
group. Furthermore, 32% and 13% of patients became pain free in the antioxidant and placebo groups, 
respectively. Thus, the results of this study seem to confirm that antioxidant supplementation is effective 
in relieving pain and reducing levels of oxidative stress in patients with chronic pancreatitis. However, 
we need studies confirming these promising results and comparing this treatment to others. 
 
13.3. Surgical or Endoscopic Approach? 
 
Many papers have been published on the possibilities offered by interventional endoscopy but, on the 
other  hand,  several  studies  have  also  been  produced  on  the  positive  results  offered  by  surgery. 
However, there are very few studies comparing the two procedures. In 2003, Dite et al. [95] published 
the results of a prospective, randomized trial comparing endoscopic and surgical therapy for chronic 
pancreatitis.  Seventy-two  patients  were  randomized;  surgery  consisted  of  resection  and  drainage 
procedures while endotherapy included sphincterotomy and stenting and/or stone removal In the entire 
group, the initial success rates were similar for both groups but, at the 5-year follow-up, the complete 
absence of pain was more frequent after surgery (37% vs. 14%), with both procedures having a similar 
rate of partial relief (49% vs. 51%). The authors concluded that surgery is superior to endotherapy for 
long-term pain reduction in patients with painful obstructive chronic pancreatitis. They also suggested 
that a better selection of patients for endotherapy could be helpful in maximizing results. Furthermore, 
due to its low degree of invasiveness, endotherapy can be offered as a first-line treatment, with surgery 
being  performed  in  case  of  failure  and/or  recurrence.  The  results  of  this  study  were  received with 
skepticism by endoscopists, mainly because the treatment was tailored to the patient whereas surgery 
involved  resection  in  the  majority  of  patients;  endoscopic  drainage  techniques  were  not  optimally 
applied  and  shock-wave  lithotripsy  was  not  utilized.  Several  other  papers  utilizing  sphincterotomy, 
dilation of strictures, and the removal of stones found endoscopic therapy to be beneficial in patients 
with chronic pancreatitis [96,97]. More recently, a new comparative study on the long term results of 
endoscopic  vs.  surgical  treatment  of  chronic  pancreatitis  patients  was  published  [98].The  authors 
randomized  39  symptomatic  patients  having  chronic  pancreatitis  with  distal  obstruction  of  the Int. J. Environ. Res. Public Health 2009, 6                 
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pancreatic duct and without an inflammatory mass: 19 underwent endoscopic transampullary drainage 
(16 of whom also underwent lithotripsy) and 20 had operative pancreaticojejunostomy. The primary end 
point was the average Izbicki pain score during 2 years of follow-up. The secondary end points were 
pain relief at the end of follow-up, physical and mental health, morbidity, mortality, length of hospital 
stay, number of procedures undergone and changes in pancreatic function. During the 24 months of 
follow-up, patients who underwent surgery, as compared with those who were treated endoscopically, 
had  significantly  lower  Izbicki  pain  scores  and  significantly  better  physical  health  summary  scores 
evaluated  using  the  Medical  Outcomes  Study  36-Item  Short-Form  General  Health  Survey 
questionnaire. At the end of the follow-up, complete or partial pain relief was achieved in 32% of 
patients assigned to endoscopic drainage as compared to 75% of patients assigned to surgical drainage; 
this difference was statistically significant. Complication rates, length of hospital stay and changes in 
pancreatic  function  were  similar  in  the  two  treatment  groups,  but  patients  receiving  endoscopic 
treatment required more procedures than the patients in the surgical group (a median of eight vs. three, 
P < 0.001). Once again, surgical drainage of the pancreatic duct was more effective than endoscopic 
treatment in patients with obstruction of the pancreatic duct due to chronic pancreatitis. What can we 
learn  from  these  results?  Is  surgery  the  best  approach  to  chronic  pancreatitis  patients?  In  the 
experimental condition evaluated by Cahen et al. [98], the answer is ‗yes‘. 
 
14. Conclusions 
 
The data discussed above show that alcoholic pancreatitis is chronic its onset. Acute pancreatitis in 
an alcoholic is generally secondary to chronic pancreatitis. Determinants of individual susceptibility to 
alcoholic  pancreatitis  still  remain  uncertain.  However,  studies  of  the  fibrogenesis  and  genetic 
modifications of alcoholic pancreatitis have improved our knowledge of this disease, demonstrating that 
SPIN-1 and CFTR gene modification may act as modifier genes. The studies in progress lead us to a 
clear  understanding  of  the  mechanisms  involved  in  the  pathogenesis  of  alcoholic  pancreatitis. 
Antioxidants may be useful in treating patients with recurrent pain; in the case of intractable pain, an 
intrathecal narcotics pump may be offered. In those patients in whom medical therapy failed to obtain 
persistent pain relief, a surgical approach should be preferred over an endoscopic approach. 
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